This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Advocates, Patients Rally To Support Sarepta Early Drug Approval Push

Stocks in this article: SRPT

DMD is caused by a genetic defect that causes loss of dystrophin, an important protein associated with muscle repair and function. DMD patients can't produce dystrophin on their own, but in the eight boys treated with eteplirsen from the beginning of the study, dystrophin production increased 47% after 48 weeks. Dystrophin production also increased 38% in the four "delayed treatment" patients.

Much of the criticism leveled against the eteplirsen data to date has focused on small trial size (only 12 patients were enrolled) and the lack of walk benefit observed in the four DMD patients treated at the 30 mg dose. Two of the four patients became wheelchair bound soon after the study started, which didn't leave enough time for etelplirsen to work, Sarepta said.

Eteplirsen works by causing the body to "skip" a mismatched section of the exon (a sequence of nucleic acids) that codes for dystrophin. By skipping exon 51, the drug enables the creation of a semi-functional dystrophin protein.

"The eteplirsen trial included a very small number of patients but the counterpoint is that these are patients with a genetic defect that is being targeted precisely by the mechanism of action of this drug," said Dr. Alex Fleming, a former FDA drug reviewer who now runs Kinexum, a healthcare consulting firm. Fleming spoke about eteplirsen on an investor conference call last month organized by Summer Street Research Partners.

The ability of eteplirsen to produce functional dystrophin, which then translates into a real clinical benefit (improved walking performance), makes it easier for FDA to approve eteplirsen under the agency's existing regulations, added Fleming.

"Subpart H accelerated approval is designed to allow FDA to approve a drug based on surrogate outcomes. What we have with eteplirsen are data that go beyond encouraging production of dystrophin but also show patients walking a clinically meaningful longer distance. Theoretically, FDA could approve eteplirsen outright and not just under subpart H."

Cure Duchenne is another DMD non-profit group that has already met with FDA and is organizing a webinar later this month that will allow DMD families to ask questions of FDA officials. The webinar will also be a good opportunity for FDA to hear directly from people directly affected by DMD, says Cure Duchenne president Debra Miller.

"We are completely supportive of the DMD community and getting this drug eteplirsen approved," said Miller, also the mother of a boy with DMD. Miller says the actions being taking now by DMD advocates are laying the groundwork for more work to be done after Sarepta has its end-of-phase II meeting with FDA.

Sarepta shares closed Monday at $23.85.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.
2 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,237.32 +168.45 0.99%
S&P 500 1,997.06 +24.32 1.23%
NASDAQ 4,609.1760 +61.3420 1.35%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs